U.S. markets open in 1 hour 27 minutes
  • S&P Futures

    4,404.25
    -28.75 (-0.65%)
     
  • Dow Futures

    34,649.00
    -94.00 (-0.27%)
     
  • Nasdaq Futures

    14,993.75
    -201.00 (-1.32%)
     
  • Russell 2000 Futures

    2,275.20
    -1.80 (-0.08%)
     
  • Crude Oil

    76.29
    +0.84 (+1.11%)
     
  • Gold

    1,735.70
    -16.30 (-0.93%)
     
  • Silver

    22.23
    -0.46 (-2.04%)
     
  • EUR/USD

    1.1690
    -0.0011 (-0.09%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • Vix

    20.55
    +2.80 (+15.77%)
     
  • GBP/USD

    1.3592
    -0.0112 (-0.82%)
     
  • USD/JPY

    111.4350
    +0.4570 (+0.41%)
     
  • BTC-USD

    42,075.93
    -1,720.53 (-3.93%)
     
  • CMC Crypto 200

    1,044.70
    -56.82 (-5.16%)
     
  • FTSE 100

    7,050.79
    -12.61 (-0.18%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

Why Senseonics Skyrocketed 340% in the First Half of 2021

·2 min read
Why Senseonics Skyrocketed 340% in the First Half of 2021
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Senseonics Holdings (NYSEMKT: SENS) skyrocketed 340% in the first half of 2021. One key early catalyst for Senseonics was a positive coverage decision in January by health insurer EmblemHealth for the Eversense continuous glucose-monitoring (CGM) system used by individuals with diabetes. In June, Senseonics reported positive results from a clinical study of its version of the Eversense device that can remain implanted for 180 days.